Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development of the former’s ...
Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback